A first-of-its-kind study identifies mechanisms that explain how a drug commonly used to treat HIV and hepatitis causes kidney disease and kidney injury. The study is published ahead of print in Function.
Enacting Medicaid expansion in Texas and increasing the use of preventive and antiviral medications could result in a decline of new HIV infections among young Black gay, bisexual, and other men who have sex with men (MSM) in Houston, reports a study in the January issue of Medical Care. The journal is published in the Lippincott portfolio by Wolters Kluwer.
The George Washington University Vaccine Research Unit in partnership with Scripps Research, IAVI, Fred Hutchinson Cancer Center (FHCC) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases Vaccine Research Center published the results of their Phase 1 Clinical Trial in Science.
Several national media outlets are reporting that the FDA is considering a new strategy for screening gay and bisexual men to help combat the national blood shortage. Florida State University’s nationally recognized experts are available to provide context to reporters who are working on this story as it develops.
This World AIDS Day, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, is calling on the health care community to increase lung cancer screening for people with HIV who are current or former heavy smokers and may be at high risk for developing the disease. As HIV- infected individuals have high smoking rates, smoking cessation should also be encouraged.
Though antiretroviral therapy has made HIV a manageable disease, people living with HIV often suffer from chronic inflammation. This can put them at an increased risk of developing comorbidities such as cardiovascular disease and neurocognitive dysfunction, impacting the longevity and quality of their lives.
A team of geriatricians at Mount Sinai’s Brookdale Department of Geriatrics and Palliative Medicine has been awarded $1.25 million from the Health Resources and Services Administration and the Keith Haring Foundation to expand Mount Sinai’s interdisciplinary model of care for older patients living with HIV.
An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.
Hosted by Chulalongkorn University the APRU APEC University Leaders' Forum 2022 is the first post-pandemic in-person APEC meeting held to foster high-level dialogue between CEOs, policy leaders, university presidents, and top researchers. This event begins Nov 15 at 9 PM EST.
People living with HIV have a significantly delayed internal body clock, consistent with the symptoms of jet lag, according to new findings reported by researchers from universities in South Africa and the UK.
Research shows that incidences of Kaposi’s sarcoma among people living with HIV have fallen significantly over the past two decades, but a new evaluation of data led by researchers at UTHealth Houston highlights a significant disparity among one particular demographic – young Black men in the American South.
Institute of Human Virology researchers at the University of Maryland School of Medicine have received two five-year awards from the National Institutes of Health’s National Cancer Institute for a total of $7.5 million. One award aims to reduce the incidence of lung cancer and other cancers associated with using tobacco in Botswana. The other is focusing on improving screening and treatment of anal precancer in Nigeria. Both grants will make use of existing HIV treatment and prevention infrastructure in low- and middle-income countries to reach people living with HIV who are most at risk for these particular types of cancers.
The Midwest AIDS Training and Education Center at the University of Illinois Chicago will expand its services nationwide with the help of a new $3 million grant.
The Wistar Insitute, William Way Community Center, Philadelphia FIGHT, BEAT-HIV Delaney Collaboratory, Philadelphia Foundation, and The Penn Center for AIDS Research are proud to announce that “The London Patient” Adam Castillejo will take part in a panel conversation and Q&A on Wednesday, October 26 from 5 to 8 pm
Inaccurate media coverage of the monkeypox outbreak has resulted in misinformation about the many ways it can be spread, resulting in stigma (shaming and biased attitudes) toward people who develop the disease. Nurses play a key role in delivering appropriate care related to monkeypox by creating safe spaces for affected individuals regardless of sexual behaviors, race and ethnicity, gender, or co-infections. These conclusions come from two papers in the November/December issue of The Journal of the Association of Nurses in AIDS Care (JANAC), the official journal of the Association of Nurses in AIDS Care. JANAC is published in the Lippincott portfolio by Wolters Kluwer.
People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 “breakthrough” infection after vaccination, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.
Mackey Reuel Friedman, PhD, MPH, has joined the Rutgers School of Public Health as an associate professor in the Department of Urban-Global Public Health.
People living with HIV must be included in clinical trials for new tuberculosis vaccine candidates currently in the development pipeline, say experts on an international panel convened last year to address gaps in the current TB vaccine landscape. Their recommendations appear in a new paper published today in The Lancet HIV.
A research team led by a University of Massachusetts Amherst scientist has made a significant genetic discovery that sheds light on the use of the drug caspofungin to treat a deadly fungal infection, Aspergillus fumigatus, which kills some 100,000 severely immunocompromised people each year.
An obscure family of viruses, already endemic in wild African primates and known to cause fatal Ebola-like symptoms in some monkeys, is “poised for spillover” to humans, according to new University of Colorado Boulder research published online Sept. 30 in the journal Cell.
New UCLA-led research suggests certain gut bacteria -- including one that is essential for a healthy gut microbiome – differ between people who go on to acquire HIV infection compared to those who have not become infected. The findings, published in the peer-reviewed journal eBioMedicine, suggest that the gut microbiome could contribute to one’s risk for HIV infection, said study lead Dr.
The Icahn School of Medicine at Mount Sinai will award its inaugural 2022 Maria I. New International Prize for Biomedical Research to cancer and HIV cellular therapy pioneer Carl H. June, MD, for his groundbreaking work in immunotherapy. Dr. June is most widely known as one of the inventors of CAR T cell therapy for cancer, which has already led to FDA-approved treatments for lymphoma, leukemia, and multiple myeloma.
As people with HIV age, their risk of heart attack increases far more if they also have untreated hepatitis C virus, even if their HIV is treated, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
LJI research shows that a "slow delivery, escalating dose" vaccination strategy can prompt B cells to spend months mutating and evolving their pathogen-fighting antibodies.
Bronx county has the country’s fifth-highest rate of HIV diagnosis—but the lowest rate in New York State for use of HIV pre-exposure prophylaxis (PrEP), medications that are extremely effective in preventing HIV infection. Physician-researchers at Albert Einstein College of Medicine and Montefiore Health System have received a five-year, $4.2 million grant from the National Institutes of Health to compare two strategies for improving PrEP access and use in the Bronx.
A lack of relatable messaging around HIV diagnoses and prevention could be a reason infection rates aren’t falling among young adults, despite dramatic decreases among all other demographics. With a $4.9 million grant from the National Institute of Mental Health, Florida State University behavioral scientist Sylvie Naar hopes to change that.
To block infection from HIV, a successful vaccine will require a combination of ingredients, including at least three antibody targets and a substance that boosts immune responses. In a step toward achieving that goal, one potential vaccine component has led to strong protection in primates by eliciting an antibody that binds to part of the virus’s outer envelope, reports a team led by researchers at the Duke Human Vaccine Institute (DHVI).
Dolutegravir-based antiretroviral therapy (ART) for HIV-1 infection is more effective in pregnancy than some other ART regimens commonly used in the U.S. and Europe, according to a study published in the New England Journal of Medicine.
UCLA research finds that a refundable State-level Earned Income Tax Credit (SEITC) of 10% or above the Federal EITC was associated with a 21% relative risk reduction in reported behavior that could put single mothers at high risk for becoming infected with HIV during the previous year. Also, a 10 percentage-point increase in SEITC was linked to a 38% relative reduction in the same reported high-risk behavior the previous year.
Sylvester Comprehensive Cancer Center researcher Emmanuel Thomas, M.D., Ph.D., F.A.A.S.L.D., has been appointed to the National Institutes of Health’s (NIH) Coinfections and HIV Associated Cancers (HCAC) study section.
JSF-2659, developed to be administered orally, could be a game changer in treating Neisseria gonorrhoeae, which is on the World Health Organization’s global list of “priority pathogens” for its resistance to existing drugs.
An embargoed study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS. Broadly neutralizing antibodies (bnAbs) are defined by their ability to neutralize multiple genetically distinct viral strains.
When expensive medicines that are proven to prevent HIV acquisition are available through employer-sponsored health insurance (ESI), annual earnings for men in same-sex couples decline and part-time employment increases. The labor market effects are largest for young white men, who are among those most likely to be taking HIV prevention drugs.
A portable diagnostic device designed by researchers at Cornell Engineering and Weill Cornell Medicine has been deployed in clinical tests in Uganda to identify cases of Kaposi sarcoma, a common yet difficult-to-detect cancer that often signals the presence of HIV infection.
A University of Utah Health-led multi-institutional research center that studies the inner workings and vulnerabilities of HIV, the human immunodeficieny virus that causes AIDS, recently received a five-year, $28 million grant renewal from the National Institutes of Health.
A University of Minnesota assistant professor is part of a team that has developed a new way to effectively deliver vaccines through the nose that could lead to better protection against diseases like HIV and COVID-19.
Behavioral scientists have long researched how to help children cope with extreme adversity – such as poverty or exposure to violence. Yanping Jiang, a researcher at the Rutgers Institute for Health, thinks she’s found the answer in rural China.
Despite an immense global effort, the HIV epidemic remains a threat and a leading cause of morbidity and mortality. Strong antiretroviral therapy (ART) continuity can suppress the viral load of HIV to undetectable levels for people living with HIV, but barriers to ART treatment continue to impact HIV epidemic control. For men and children, ART continuity and thus viral load suppression (VLS) are disproportionately low, particularly in sub-Saharan Africa. To address these barriers, in September 2020, WI-HER—through the USAID Social and Behavior Change Activity (SBCA)—implemented the innovative iDARE methodology developed by Dr Taroub Harb Faramand.
Special issue includes research and commentary addressing important considerations for national PrEP program that would lower prices and expand access.
Scientists, doctors and other health professionals from the HIV Vaccine Trials Network (HVTN) will present research findings and other HIV-related news at AIDS 2022, the International AIDS Conference taking place virtually and in person in Montreal, Canada, July 29 to Aug. 2.
In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.